Digital health company Butterfly Network has signed an agreement with Mendaera for the commercialisation of a next-generation interventional robotic system.

The robotic system is powered by Ultrasound-on-Chip technology from Butterfly.

On commercialisation, the agreement involves sharing revenue for each sold unit.

Designed to be connected through Butterfly's software development kit known as Butterfly Garden, Mendaera’s robotic technology is compatible with Butterfly’s semiconductor-based ultrasound device.

Together, they form a system aimed at enhancing precision and consistency in various image-guided, needle-based interventions.

Butterfly Network chief strategy officer Darius Shahida said: “Mendaera’s robotic system is perfectly suited to leverage Butterfly’s proprietary Ultrasound-on-Chip by benefiting from the wide array of ultrasonic sensing applications that only our chip can offer.

“We are excited to welcome the Mendaera team as a Powered by Butterfly partner and believe our joint solution will expand Butterfly’s reach and clinical impact into the interventional space.”

Furthermore, Mendaera concluded the research and design process for the new robotic system.

Both companies expect to submit the product to the US Food and Drug Administration (FDA) by 2025.

Mendaera co-founder and CEO Josh DeFonzo said: “At Mendaera, we envision a world where high-quality intervention is available at every care facility, for each and every patient encounter.

“It was a clear choice for us to collaborate with Butterfly on our technology roadmap, given their unique and programmable Ultrasound-on-Chip platform and aligned mission to make ultrasonic imaging and intervention ubiquitous.”

In August 2023, Mendaera announced that it had successfully secured $24m in Series A funding. Lux Capital led the funding round, with participation from Operator Partners, Founders Fund, Allen & Company, and Parade Ventures.